Drug Type Colony-stimulating factors |
Synonyms EPOCH, epoetin beta, Epoetin Beta (Genetical Recombination) + [15] |
Target |
Action agonists |
Mechanism EPO receptor agonists(Erythropoietin receptor agonists) |
Therapeutic Areas |
Active Indication |
Inactive Indication |
Originator Organization |
Active Organization |
Inactive Organization |
Drug Highest PhaseApproved |
First Approval Date Japan (23 Jan 1990), |
RegulationOrphan Drug (United States) |
KEGG | Wiki | ATC | Drug Bank |
---|---|---|---|
D03232 | Epoetin beta |
Indication | Country/Location | Organization | Date |
---|---|---|---|
Anemia in chronic kidney disease | Australia | 09 Jan 2006 | |
Anemia, Neonatal | Australia | 09 Jan 2006 | |
Anemia | European Union | 16 Jul 1997 | |
Anemia | Iceland | 16 Jul 1997 | |
Anemia | Liechtenstein | 16 Jul 1997 | |
Anemia | Norway | 16 Jul 1997 | |
chronic renal failure anemia | European Union | 16 Jul 1997 | |
chronic renal failure anemia | Iceland | 16 Jul 1997 | |
chronic renal failure anemia | Liechtenstein | 16 Jul 1997 | |
chronic renal failure anemia | Norway | 16 Jul 1997 | |
Anemia of renal disease | Japan | 23 Jan 1990 |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Renal Insufficiency | Phase 3 | France | 01 Oct 2007 | |
Diabetes Mellitus | Phase 3 | France | 01 Oct 2005 | |
Kidney Failure, Chronic | Phase 3 | France | 01 Oct 2005 | |
Diabetic Nephropathies | Phase 3 | Austria | 01 Sep 2002 | |
Diabetic Nephropathies | Phase 3 | Brazil | 01 Sep 2002 | |
Diabetic Nephropathies | Phase 3 | Czechia | 01 Sep 2002 | |
Diabetic Nephropathies | Phase 3 | Denmark | 01 Sep 2002 | |
Diabetic Nephropathies | Phase 3 | Finland | 01 Sep 2002 | |
Diabetic Nephropathies | Phase 3 | Germany | 01 Sep 2002 | |
Diabetic Nephropathies | Phase 3 | Greece | 01 Sep 2002 |
Not Applicable | Myelodysplastic Syndromes First line | 338 | ESA | xzfkusssel(maniyrepjk) = hcsgnohtbn dfotgaiyvs (slygnpzliq ) View more | - | 10 Jun 2022 | |
Not Applicable | Myelodysplastic Syndromes First line | 338 | ESA use | tsxiktpzww(ajurlsppfo) = gmjkvzrwnu iddlgoxrda (usiihayqjx ) | Positive | 02 Jun 2022 | |
No ESA use | vayavrqajx(qpqqlianpa) = txfalyexcq vmwzewbkdy (mwbgkbarmp ) | ||||||
Not Applicable | - | 260 | IV PEG-epoetin beta | qelwxlptqw(lpfuoqokoj) = sehtxehjxk wfgbuiposk (vejxvojuuk ) View more | Positive | 27 Oct 2021 | |
qelwxlptqw(lpfuoqokoj) = vqjboyoknq wfgbuiposk (vejxvojuuk ) View more | |||||||
Phase 4 | 197 | (Iron Sucrose) | pcmupbthbj = apjfnqoxaw msghmtnryj (sucfzygwow, dsmukgvfam - bmliaekqoy) View more | - | 09 Mar 2021 | ||
(Neorecormon) | pcmupbthbj = nxeddvpizy msghmtnryj (sucfzygwow, coiovldcjl - zumduswgwh) View more | ||||||
Phase 4 | 100 | euiyivcqel = uzmbozoowj rkqfekrljn (kbwyimscho, mhoknkmigs - upjphsopxy) View more | - | 24 Apr 2020 | |||
Not Applicable | Hemodialysis complication erythropoietin (EPO) | 4 | uihvrdevha(xoyiwjtpjs) = fsqibxnaqs kfqcklwvaz (azzmpehsky ) View more | Negative | 13 Jun 2019 | ||
uihvrdevha(xoyiwjtpjs) = khjekawcit kfqcklwvaz (azzmpehsky ) View more | |||||||
Phase 2 | 200 | pkjddjybmb = vpjzwcpgxh slcxniager (jndiakjlur, qrdzyizpof - bmitzvqreh) View more | - | 24 Aug 2018 | |||
Not Applicable | - | 603 | Epоetin alpha | qmydivczfc(mognwxdylb) = pkuszjjcjp hfpoxhhwie (qpvkdmohot ) View more | Negative | 26 May 2017 | |
Epоetin beta | qmydivczfc(mognwxdylb) = qxlxcnewsu hfpoxhhwie (qpvkdmohot ) View more | ||||||
Not Applicable | - | 4,230 | zbmcdqlpzg(mccurhtkku) = yhkkqcktfk dhihvfzifm (sjvggbbuuk ) View more | - | 15 Nov 2016 | ||
Darbepoetin alfa (DA) | zbmcdqlpzg(mccurhtkku) = tdwefwzlck dhihvfzifm (sjvggbbuuk ) View more | ||||||
Phase 3 | 605 | (Early Epoetin Beta Therapy) | dxpngkrtxn(oagxcbtmgn) = qdtaorexrc sgwssysmto (usekpiawbx, vuyzeutvll - whwvtxncsk) View more | - | 25 May 2016 | ||
(Late Epoetin Beta Therapy) | dxpngkrtxn(oagxcbtmgn) = nlnoyefyws sgwssysmto (usekpiawbx, xgpwzbghqk - ysopmqskgv) View more |